Biomerica INC (BMRA) — SEC Filings

Overview

Biomerica INC (BMRA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 16, 2025: Biomerica Inc. filed an 8-K on December 16, 2025, reporting on a submission of matters to a vote of security holders as of December 12, 2025. The company, incorporated in Delaware, is involved in in vitro & in vivo diagnostic substances.

Sentiment Summary

Across 23 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 16 neutral, 4 mixed. The dominant filing sentiment for Biomerica INC is neutral.

Filing Type Overview

Biomerica INC (BMRA) has filed 8 8-K, 1 DEFA14A, 2 DEF 14A, 6 10-Q, 1 10-K/A, 2 10-K, 2 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (23)

• Biomerica Inc. Files 8-K on Security Holder Vote Matters — 8-K · Dec 16, 2025 Risk: medium
  Biomerica Inc. filed an 8-K on December 16, 2025, reporting on a submission of matters to a vote of security holders as of December 12, 2025. The company, incor
• Biomerica Inc. Files Definitive Additional Materials Proxy Statement — DEFA14A · Oct 23, 2025 Risk: low
  Biomerica Inc. filed a Definitive Additional Materials proxy statement on October 23, 2025. The filing pertains to matters requiring shareholder approval, as in
• Biomerica Seeks Massive Share Authorization Hike, Dilution Risk Looms — DEF 14A · Oct 20, 2025 Risk: high
  BIOMERICA, INC. (BMRA) is holding its Annual Meeting on December 12, 2025, where stockholders will vote on several key proposals. The company seeks to elect fiv
• Biomerica Posts Q1 Profit Amid Sales Dip, Going Concern Doubts Persist — 10-Q · Oct 14, 2025 Risk: high
  BIOMERICA INC (BMRA) reported a significant turnaround in net income for the three months ended August 31, 2025, achieving a net income of $2,000 compared to a
• BIOMERICA, INC. Files 8-K: Director & Officer Changes — 8-K · Oct 8, 2025 Risk: medium
  On October 7, 2025, BIOMERICA, INC. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also inc
• Biomerica Amends 10-K, Shakes Up Board & Governance — 10-K/A · Sep 26, 2025 Risk: medium
  BIOMERICA INC's 10-K/A filing, dated September 26, 2025, primarily amends Part III of its 2025 Annual Report, focusing on corporate governance, executive compen
• Biomerica Shifts to Commercialization, Cuts R&D Amid Sales Dip — 10-K · Aug 29, 2025 Risk: high
  BIOMERICA INC (BMRA) reported a slight decrease in net sales to $5,311,000 for the fiscal year ended May 31, 2025, down from $5,415,000 in fiscal year 2024. The
• Biomerica Elects New Directors, Appoints New CFO — 8-K · Jun 6, 2025 Risk: medium
  On June 4, 2025, BIOMERICA, INC. filed an 8-K report detailing several key events. The company announced the election of two new directors, Dr. Robert L. Smith
• BIOMERICA, INC. Files 8-K with Corporate Updates — 8-K · Apr 16, 2025 Risk: medium
  On April 15, 2025, BIOMERICA, INC. filed an 8-K report detailing several key events. These include material modifications to the rights of security holders, ame
• Biomerica Inc. Files Q3 2025 10-Q Report — 10-Q · Apr 14, 2025 Risk: medium
  Biomerica Inc. filed its 10-Q for the period ending February 28, 2025. The company, previously known as NMS Pharmaceuticals Inc., is based in Irvine, CA, and op
• Biomerica Inc. Files Q2 FY2025 10-Q — 10-Q · Jan 14, 2025 Risk: medium
  Biomerica Inc. filed its 10-Q for the period ending November 30, 2024. The company reported financial results for the second quarter of fiscal year 2025. Specif
• Biomerica Inc. Reports on Security Holder Vote — 8-K · Dec 17, 2024 Risk: low
  Biomerica Inc. filed an 8-K on December 17, 2024, reporting on a submission of matters to a vote of security holders that occurred on December 13, 2024. The com
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Biomerica Inc. Faces Delisting Concerns — 8-K · Nov 6, 2024 Risk: high
  Biomerica Inc. filed an 8-K on November 6, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as
• Biomerica Inc. Files Q1 2025 10-Q — 10-Q · Oct 15, 2024 Risk: low
  Biomerica Inc. filed a 10-Q for the period ending August 31, 2024. The company, previously known as NMS Pharmaceuticals Inc., is involved in diagnostic substanc
• Biomerica Inc. Files Definitive Proxy Statement — DEF 14A · Sep 30, 2024 Risk: low
  Biomerica Inc. filed its definitive proxy statement (DEF 14A) on September 30, 2024, for its fiscal year ending May 31, 2024. The filing details information rel
• Biomerica Inc. Files 2024 10-K — 10-K · Aug 28, 2024 Risk: medium
  Biomerica Inc. filed its 10-K for the fiscal year ending May 31, 2024, reporting on its operations in the in vitro and in vivo diagnostic substances sector. The
• Biomerica Appoints New Directors, Updates Executive Contracts — 8-K · Jun 28, 2024 Risk: medium
  On June 26, 2024, BIOMERICA, INC. announced changes in its board of directors and executive compensation. Specifically, the company elected two new directors, D
• BIOMERICA, INC. Files 8-K: Material Agreement & Listing Concerns — 8-K · May 10, 2024 Risk: medium
  On May 7, 2024, BIOMERICA, INC. filed an 8-K report detailing a material definitive agreement. The company, formerly known as NMS PHARMACEUTICALS INC, is incorp
• Biomerica Inc. Files 10-Q for Period Ending February 29, 2024 — 10-Q · Apr 12, 2024 Risk: low
  BIOMERICA INC (BMRA) filed a Quarterly Report (10-Q) with the SEC on April 12, 2024. Biomerica Inc. filed a 10-Q report for the period ending February 29, 2024.
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Wasatch Advisors LP Discloses 5.7% Stake in Biomerica Inc. — SC 13G · Feb 9, 2024 Risk: low
  Wasatch Advisors LP, an investment adviser, reported on February 9, 2024, that it owns 953,264 shares of Biomerica, Inc. common stock, representing 5.7% of the
• Biomerica Inc. Files 10-Q for Period Ending November 30, 2023 — 10-Q · Jan 16, 2024 Risk: low
  BIOMERICA INC (BMRA) filed a Quarterly Report (10-Q) with the SEC on January 16, 2024. Biomerica Inc. filed a 10-Q report for the period ending November 30, 202

Risk Profile

Risk Assessment: Of BMRA's 21 recent filings, 4 were flagged as high-risk, 10 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Biomerica INC's most recent 10-Q filing (Oct 14, 2025):

• Revenue: $1,380,000
• Net Income: $2,000
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $3,053,000
• Operating Margin: -111.7%
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Zackary S. Irani
• Allen Barbieri
• Jane Emerson, M.D., Ph.D.
• Gary Lu
• David Moatazedi
• Eric Bing Chin
• Zackary Irani
• Catherine Coste
• Dr. Robert L. Smith
• Mr. David L. Smith
• Ms. Jane Doe
• Mr. John Roe
• Mr. Jerry L. Lytle
• Mr. Robert J. Lytle

Industry Context

Biomerica, Inc. operates in the diagnostics and medical device industry, a sector characterized by rapid technological advancements, stringent regulatory oversight (FDA, etc.), and competitive pressures from both large established players and smaller innovative companies. The industry requires significant R&D investment and faces challenges related to market access, reimbursement, and intellectual property protection. Trends include a growing demand for point-of-care diagnostics, personalized medicine, and digital health solutions.

Top Tags

10-Q (5) · financials (4) · corporate-governance (3) · SEC Filing (3) · diagnostics (3) · shareholder-vote (2) · proxy-statement (2) · governance (2) · Corporate Governance (2) · Executive Compensation (2)

Executive Compensation

From the most recent DEF 14A filing (Oct 20, 2025):

• Zackary S. Irani — Chief Executive Officer and Director

Key Numbers

• Proposed maximum authorized shares of common stock: 300,000,000 — Increase from current 25,000,000 shares, representing an 1,100% increase
• Current authorized shares of common stock: 25,000,000 — Baseline before proposed amendment
• Additional shares for 2024 Stock Incentive Plan: 200,000 — Proposed increase in shares authorized for employee compensation
• Shares of common stock outstanding: 2,947,966 — As of the Record Date, October 15, 2025
• Percentage of shares beneficially owned by Zackary Irani: 8.3% — Largest individual shareholder among named executives and directors
• Percentage of shares beneficially owned by all executive officers and directors as a group: 18.0% — Total ownership by the seven-person group
• Par value per share of common stock: $0.08 — Stated par value of Biomerica's common stock
• Approximate number of stockholders of record: 860 — As of the Record Date, October 15, 2025
• Date of Annual Meeting: December 12, 2025 — Key date for shareholder votes
• Record Date for voting: October 15, 2025 — Date to determine eligible stockholders for the Annual Meeting
• Net Income: $2,000 — Significant turnaround from a $1,316,000 net loss in Q1 2024.
• Net Sales: $1,380,000 — Decreased by 23.6% from $1,807,000 in Q1 2024.
• Other Income: $1,123,000 — Increased substantially from $56,000 in Q1 2024, driving profitability.
• Gross Profit: $424,000 — Increased by 46.7% from $289,000 in Q1 2024.
• Accumulated Deficit: $53,200,000 — Indicates significant historical losses and contributes to going concern doubt.

Forward-Looking Statements

• {"claim":"Other institutional investors may increase their positions in Biomerica, Inc. following Wasatch Advisors LP's disclosure.","entity":"Biomerica, Inc.","targetDate":"Within 6 months","confidence":"medium"}
• {"claim":"Biomerica, Inc.'s stock price could see a short-term positive reaction due to increased investor confidence.","entity":"Biomerica, Inc.","targetDate":"Within 1 month","confidence":"medium"}

Related Companies

CTRE · RNLX · EOLS · VERB · FSV · AVGO · BMCA

Frequently Asked Questions